🇧🇷Brazil

Superfaturamento em Aquisição de Medicamentos (Viagra) - Falta de Verificação de Preço de Mercado

1 verified sources

Definition

TCU opened formal investigation into Viagra procurement superfaturamento (overcharging). Lack of price benchmarking against commercial pharmacy rates + manual invoice approval enabled systematic overpayment on pharmaceutical procurement.

Key Findings

  • Financial Impact: Estimated R$ 500k-2M overpayment on 35k units (logic estimate: if 5-10x markup on pharmaceutical, and unit cost R$ 15-30 retail vs. R$ 75-150 invoiced)
  • Frequency: Single procurement incident identified; risk applies to all pharmaceutical procurements
  • Root Cause: Absence of pharmaceutical pricing database in invoice approval workflow; no benchmarking against ANVISA-registered prices or retail pharmacy comparisons; manual invoice approval without access to market pricing tools

Why This Matters

The Pitch: Armed Forces waste hundreds of thousands on pharmaceutical overpayment due to absent price verification at invoice stage. Real-time ANVISA/pharmacy pricing API integration at invoice approval prevents overpayment on controlled medications.

Affected Stakeholders

Pharmaceutical Procurement Officers, Invoice Approvers (Medical Services), Price Verification Staff, Accounts Payable

Deep Analysis (Premium)

Financial Impact

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Current Workarounds

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Get Solutions for This Problem

Full report with actionable solutions

$99$39
  • Solutions for this specific pain
  • Solutions for all 15 industry pains
  • Where to find first clients
  • Pricing & launch costs
Get Solutions Report

Methodology & Sources

Data collected via OSINT from regulatory filings, industry audits, and verified case studies.

Evidence Sources:

Related Business Risks

Lançamentos Antecipados de Pagamento sem Desembolso Efetivo (Fraude de Liquidação)

R$ 400 milhões+ annually (confirmed in specific fiscal periods by TCU audit); conservative estimate across full audit period: R$ 2-3 bilhões in suspicious payment transactions

Cartel de Fornecedores ('Clube de Vendas') em Licitações de Alimentos e Suprimentos

R$ 154 milhões em 2020-2021 (6 months); extrapolated annual loss: R$ 250+ milhões

Fraude Generalizada em Fundações de Apoio Militar (Desvios via Contratos Fraudulentos)

R$ 15.731.972,66 (IME case, single sentence); estimated full fraud ecosystem (2000-2021): R$ 100+ milhões across all Army support foundations

Superfaturamento em Compras no Exterior (Overpayment sem Benchmarking de Preço)

R$ 2-4 bilhões (logic estimate based on: R$ 23B total spend across 5 commissions over 4 years; ~10-15% of audited transactions showing pricing anomalies)

Uso Não-Autorizado de Cartão de Crédito Privado para Despesas Públicas (Não-Conformidade de Instrumento de Pagamento)

R$ 0 direct loss quantified; but exposure to: TCU audit exceptions (R$ 100k-500k per exception notice); potential Fiscal Responsibility Law penalties; audit costs (estimated 200-400 hours/year of TCU staff review)

Sobrecustos em Modificações Contratuais e Licitações Direcionadas

LOGIC ESTIMATE: 5–15% cost overrun on annual defense procurement (estimated R$ 15–45 billion market = R$ 750 million to R$ 6.75 billion annually in preventable overruns)

Request Deep Analysis

🇧🇷 Be first to access this market's intelligence